| Pair Name | Ginkgolide B, Cisplatin | ||
| Phytochemical Name | Ginkgolide B (PubChem CID: 6324617 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Ginkgolide B, Cisplatin | |||
| Disease Info | [ICD-11: 2B66.Z] | Oral cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Expression | PTAFR | hsa5724 | |
| In Vitro Model | Ca9-22 | Gingival squamous cell carcinoma | Homo sapiens (Human) | CVCL_1102 |
| HO-1-N-1 | Buccal mucosa squamous cell carcinoma | Homo sapiens (Human) | CVCL_1284 | |
| Result | These results suggest that PAFR is a therapeutic target for modulating CDDP sensitivity in OSCC cells. Thus, GB may be a novel drug that could enhance combination chemotherapy with CDDP for OSCC patients. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Ginkgolide B Regulates CDDP Chemoresistance in Oral Cancer via the Platelet-Activating Factor Receptor Pathway. Cancers (Basel). 2021 Dec 15;13(24):6299. doi: 10.3390/cancers13246299. | Click |
